自愿,强迫和联合运动对改善阿尔茨海默病病因型的差异效应和潜在机制
Wanyi Li1, Shiyu Chen2, Zhitao Liu3
1Department of Physiology and Pharmacology, Health Science Center, Ningbo University, Ningbo, Zhejiang 315211, PR China; College of Physical Education and Sport Science, Fujian Normal University, Minhou County, Fuzhou 350117, PR China.
Experimental neurology
|March 13, 2026
概括
不同的运动类型对阿尔茨海默病 (AD) 模型显示出独特的益处. 强迫性炼提供了持续的认知改善,而所有炼类型都能促进神经发生,并可能涉及BDNF信号通路.
科学领域:
- 神经科学是一个神经科学.
- 运动生理学 运动生理学
- 神经退行性疾病 神经退行性疾病
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是粉样β (Aβ) 斑块和团.
- 目前的AD治疗方法有限,需要探索运动等替代干预措施.
- 在阿尔茨海默氏症中,各种运动方式的差异性影响和机制尚不清楚.
研究的目的:
- 在小鼠模型中研究自愿性,强迫性和联合运动对AD病理学的独特治疗效果.
- 评估运动对抑郁症类行为,认知,神经发生和AD中的分子途径的影响.
- 为了研究急性运动对阿尔茨海默病患者皮质活动的影响.
主要方法:
- 利用Aβ寡合体诱导的AD小鼠模型来测试自愿的轮子运行,强制的跑步机运行和联合炼.
- 使用强迫游泳,尾部悬挂,新型物体识别和莫里斯水迷宫测试来评估行为.
- 通过免疫光分析了神经发生,通过西部斑块和血清代谢物表达蛋白质;通过功能近红外光谱 (fNIRS) 进行了临床试验.
主要成果:
- 所有的炼类型都改善了AD小鼠的抑郁类行为和短期记忆;只有强迫炼产生了持续的长期记忆益处.
- 运动增强了海马神经发生,促进新生儿细胞的增殖和分化.
- 强迫性炼显著增加了新生儿成熟的神经元,神经保护与BDNF-TrkB信号传递和亡调节有关. 代谢学揭示了运动诱导的代谢物和神经功能之间的相关性.
- 在阿尔茨海默病患者中,急性自愿运动增加了左前额叶皮质的活动,而强迫运动则激活了运动皮质.
结论:
- 独特的长期运动干预在AD小鼠模型中表现出独特的神经保护特征,防止AD小鼠模型中的Aβ寡合体毒性.
- 急性运动方式对阿兹海默症患者的皮质激活和功能连接有不同的影响.
- 这项研究为改善AD神经病理的运动方式提供了新的见解.
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K


